We recently identified a polymorphism upstream of interleukin (IL)-28B to be associated with a 2-fold difference in sustained virologic response (SVR) rates to pegylated interferon-alfa and ribavirin therapy in a large cohort of treatment-naive, adherent patients with chronic hepatitis C virus genotype 1 (HCV-1) infection. We sought to confirm the polymorphism's clinical relevance by intention-to-treat analysis evaluating on-treatment virologic response and SVR. METHODS: HCV-1 patients were genotyped as CC, CT, or TT at the polymorphic site, rs12979860. Viral kinetics and rates of rapid virologic response (RVR, week 4), complete early virologic response (week 12), and SVR were compared by IL-28B type in 3 self-reported ethnic groups: Caucasians (n ϭ 1171), African Americans (n ϭ 300), and Hispanics (n ϭ 116). RESULTS: In Caucasians, the CC IL-28B type was associated with improved early viral kinetics and greater likelihood of RVR (28% vs 5% and 5%; P Ͻ .0001), complete early virologic response (87% vs 38% and 28%; P Ͻ .0001), and SVR (69% vs 33% and 27%; P Ͻ .0001) compared with CT and TT. A similar association occurred within African Americans and Hispanics. In a multivariable regression model, CC IL-28B type was the strongest pretreatment predictor of SVR (odds ratio, 5.2; 95% confidence interval, 4.1-6.7). RVR was a strong predictor of SVR regardless of IL-28B type. In non-RVR patients, the CC IL-28B type was associated with a higher rate of SVR (Caucasians, 66% vs 31% and 24%; P Ͻ .0001). CONCLUSIONS: In treatment-naive HCV-1 patients treated with pegylated interferon and ribavirin, a polymorphism upstream of IL-28B is associated with increased on-treatment and sustained virologic response and effectively predicts treatment outcome.
care is pegylated-interferon-alfa (pegIFN-alfa) and ribavirin (RBV) combination therapy. However, of patients infected with genotype 1 HCV (HCV-1), the most common HCV genotype in North America, Europe, and Japan, only approximately 40% are cured by standard therapy. [2] [3] [4] [5] [6] Furthermore, therapy may be associated with considerable toxicity. Therefore, the ability to prospectively identify individual patients who are likely to respond to treatment would be clinically valuable.
A number of pretreatment host and viral factors have been associated with treatment outcome in HCV-1. 6 These include baseline viral load, age, sex, body mass index (BMI), insulin resistance, hepatic steatosis, and hepatic fibrosis. African American ancestry is a powerful negative predictive factor for sustained virologic response (SVR). 7, 8 The rate of plasma HCV-RNA decline during treatment is predictive of treatment outcome, and virologic responses at week 4 (rapid virologic response [RVR] ) and week 12 (early virologic response [EVR] ) are additional key therapeutic milestones. However, our understanding of the genetic determinants of treatment outcome has been limited.
We recently performed a genome-wide association study to identify genetic determinants of treatment response in HCV-1 patients treated with pegIFN plus RBV. 9 We identified a single nucleotide polymorphism (SNP) upstream of the gene IL-28B on chromosome 19, coding for IFN--3, which was associated with an approximately 2-fold difference in SVR rates in patients of European, African American, or Hispanic ancestry. 9 The analysis was restricted to 1137 of 1671 patients, in which nonresponders were required to have been more than 80% adherent to both pegIFN and RBV dosing, and ethnicity was defined by genetic ancestry. 9 The importance of this genetic region as a determinant of treatment response has now been confirmed by 2 independent genome-wide association studies. 10, 11 Interleukin (IL)-28B polymorphism also has been shown to be associated with spontaneous clearance after HCV infection. 12, 13 In this intention-to-treat (ITT) analysis of the discovery cohort, we sought to interpret the IL-28B polymorphism in a more detailed clinical context to determine how knowledge of this genetic information might impact physician practice. We describe how the genotype of the IL-28B polymorphism influences on-treatment virologic responses, as well as relapse rates, and consider in detail the effect of the polymorphism in the context of other variables predictive of antiviral therapy outcome. Our analyses included all patients, regardless of their level of adherence to therapy, and ethnicity was determined by subject self-report, as it would be in a clinical practice setting.
Materials and Methods Patients
The study population included 1604 of 3070 patients who were enrolled in the IDEAL study and consented to genetic testing (ClinicalTrials.gov number, NCT00081770). 6 In addition, 67 patients were included from a second randomized controlled trial. 7 For all 1671 patients, the protocol-specified treatment duration was 48 weeks, with an additional 24 weeks of follow-up evaluation. Clinical and laboratory data were collected as described previously. 6, 7 Ethnicity was defined by patient self-report, and not genetically inferred ancestry as in the analysis of Ge et al. 9 A discrepancy between self-report and genetic ancestry was noted in 130 (8%) patients. All patients for whom the polymorphism of interest was genotyped successfully were included in this analysis, which therefore included 491 patients excluded from the analysis by Ge et al 9 (336 [21%] on the basis of nonadherence).
Genotyping
A total of 1671 patients were genotyped using the Illumina Human610-quad BeadChip (Illumina, San Diego, CA) as previously described. 9 We selected the discovery SNP, rs12979860, for this study. Genotype at the polymorphic site rs12979860 on chromosome 19 was suitable for analysis in 1628 patients. For simplicity, we refer to an IL-28B polymorphism throughout this article, noting that the association SNP actually lies 3 kilobases upstream of the IL-28B gene. Genotype was defined as CC, CT, or TT IL-28B type.
Treatment Efficacy Assessments
HCV-RNA levels were measured using sensitive reverse-transcription polymerase chain reaction assays. In the IDEAL study, the Cobas TaqMan assay (Roche Molecular Diagnostics, Pleasanton, CA) was used, which has a lower limit of quantitation of 27 IU/mL. 6 In the earlier study by Muir et al, 7 the NGI SuperQuant assay was used (National Genetics Institute, Culver City, CA), which has a lower limit of quantitation of 39 IU/mL. Viral load was measured at baseline; treatment weeks 2, 4, 12, 24, and 48; and follow-up evaluation weeks 4, 12, and 24 (patients from the study by Muir et al 7 did not have viral load measured at week 2 or week 4). On-treatment responses were defined by undetectable plasma HCV-RNA levels at the following time points: ultrarapid virologic response at 2 weeks; RVR at 4 weeks; complete EVR (cEVR) at 12 weeks; and end-of-treatment response at 48 weeks. 14 SVR was defined by undetectable HCV-RNA levels at 24 weeks posttreatment (or 12 weeks posttreatment if 24-week follow-up data were not available; n ϭ 40). Relapse was defined as detectable HCV-RNA levels during follow-up evaluation in patients who achieved end-of-treatment response.
value of less than .05. Analysis of on-treatment response by IL-28B polymorphism was performed in 3 separate ethnic populations: Caucasians, African Americans, and Hispanics (on-treatment responses for the 41 patients of "other" ethnicity are not described). A linear mixed-effects model that included subject-specific intercept and slope and accounted for the left censoring of the viral load measurements was built to analyze the association of IL-28B SNP genotype and race on the log 10 viral load within the first 12 weeks of treatment. 15 Multivariable logistic regression with backward elimination was used to identify baseline factors in the entire cohort associated with SVR. Separate models were not constructed for each ethnicity; rather, ethnicity was included as a covariate in the model. Additional covariates considered for inclusion in the model included baseline viral load (log 10 IU/mL), fasting blood sugar level, liver fibrosis stage, age, BMI, serum alanine aminotransferase (ALT) level, hepatic steatosis grade, ribavirin starting dose, sex, pegIFN (dose/ type), IL-28B type, and IL-28B type by ethnicity interaction. IL-28B polymorphism was evaluated according to CC versus non-CC IL-28B type for the regression modeling. A significance level of 0.05 was used for removal from the model. A second model was built to consider the effect of IL-28B polymorphism for predicting SVR after adjusting for RVR, which included all subjects with measured covariates and virologic data at week 4 (1422 subjects). In addition to the covariates described earlier, we grouped week 4 response and IL-28B polymorphism as a 3-level variable: week 4 responders (RVR); week 4 nonresponders, CC genotype; and week 4 nonresponders, non-CC genotype; there were too few patients without the CC genotype who were also week 4 responders to subset the week 4 responders by genotype. All analyses were performed using R statistical software (R Foundation for Statistical Computing, http:// www.R-project.org) and SAS version 9.1 (SAS Institute, Cary, NC).
Results

Characteristics of the Study Patients
A majority of the patients were male (61%) and older than 40 years of age (Table 1) . Most patients were Caucasian (72%); African Americans comprised 18% of patients, and Hispanics comprised 7%. Compared with Caucasians, African Americans were older, more likely to have a BMI of 30 kg/m 2 or greater, and an increased baseline fasting glucose level, and less likely to have an abnormal serum ALT level. Allocation of pegIFN type was balanced between and within each ethnic group. African American patients were less likely to have been assigned an RBV dose greater than 13 mg/kg/day. The frequency of the IL-28B SNP genotype differed between ethnic groups (P Ͻ .0001) (Table 1) , as previously described. 9 The CC genotype was observed most frequently in Caucasians (37%), followed by Hispanics (29%) and African Americans (14%). The TT genotype was more common in African Americans (37%) than Hispanics (22%) or Caucasians (12%).
Viral Kinetics
As previously reported, a small but statistically significant difference in median viral load at baseline was noted according to IL-28B type, with higher levels present in CC patients (Caucasians, 6.6 (6.1-6.9) vs 6.4 (6.0 -6.7) vs 6.3 (5.9 -6.6) log 10 IU/mL for CC, CT, and TT patients, respectively, Supplementary Table 1) . 9 However, when viral load was considered according to the threshold of 600,000 IU/ mL, the proportion of patients with high baseline viral load did not differ by IL-28B type.
On-treatment, differences in viral load reduction between genotypes were detectable as early as week 2, the earliest time point evaluated ( Figure 1 ; Supplementary Table 2 ). Among Caucasians, median reductions of viral load at week 2 were as follows: 2.6, 0.9, and 0.6 log 10 IU/mL for patients with the CC, CT, and TT IL-28B types, respectively (P Ͻ .0005). Despite ongoing viral decline, the difference was of similar magnitude at weeks 4 and 12, corresponding to increased rates of RVR and cEVR in patients with the CC genotype ( Figure 2 and Tables 2 and 3 ). The rate of viral load reduction in African American and Hispanic patients also was more rapid in those with the CC IL-28B type. However, among African American CC patients, the magnitude of viral decline was less than that observed in Caucasian CC patients at all times (weeks 2, 4, and 12; P Ͻ .0020; Figure 1 , Supplementary Table 2) . Linear mixed-effects modeling confirmed that viral load declined more for patients with the CC versus non-CC IL-28B type (delta, 0.6190; 95% confidence interval [CI], 0.5562-0.6817 log 10 IU/mL/wk; Supplementary Table 3) . This effect was independent of ethnic background, which also was associated with the rate of viral decline. There was no significant difference in the rate of decline between patients with the CT and TT genotypes (P ϭ .1468).
Viral Clearance-On-Treatment and SVR
Within each ethnic group, the CC IL-28B type was associated with higher on-treatment response rates at all time points (4, 12, and 48 weeks) ( Figure 2 and Table 2 ). In Caucasians who were CC, 87% attained a cEVR, 10% achieved a pEVR, and only 3% did not achieve a 2-log 10 IU/mL reduction in viral load at week 12 of treatment.
Within all populations, the CC IL-28B type was associated with a greater than 2-fold increase in SVR compared with the TT IL-28B type. The rate of SVR observed in Caucasians with the CC IL-28B type (69%) was higher than in either African Americans (48%) or Hispanics (56%) (P ϭ .0079). The CT IL-28B type consistently was associated with numerically higher virologic responses than TT; however, the differences were small and not statistically significant ( Figure 2 and 
SVR Rates According to Week 4 and Week 12 Responses
The CC IL-28B type increased the proportion of patients who attained RVR; in those who achieved this key therapeutic milestone, SVR rates were high, independent of IL-28B SNP genotype (Table 3 ). In contrast, in patients who did not achieve RVR, the effect of IL-28B SNP genotype was strikingly different-SVR rates were significantly higher in patients with the CC IL-28B type in all populations (Caucasian non-RVR:SVR ϭ 66% for CC vs 31% for CT vs 24% for TT; P Ͻ .0001). In patients who were CC at the polymorphic site, the rate of cEVR was high in all populations ( Table 2 ). Rates of SVR were higher post-cEVR than in patients attaining only pEVR, but the predictive utility of the IL-28B polymorphism was not strong once week 12 virologic response was available (Table 3) .
Test Characteristics for IL-28B SNP Genotype Compared With RVR
The performance of the IL-28B SNP genotype (CC vs non-CC) as a binary predictor for SVR was evaluated in the 3 major population groups (Table 4) . In Caucasian patients, having the CC IL-28B type was more sensitive and had a higher negative predictive value for SVR than RVR; however, RVR had superior positive predictive value and specificity for SVR. Importantly, the CC IL-28B type was present in 37% of the Caucasian population, whereas only 14% attained an RVR. A similar pattern was observed in African American and Hispanic patients.
Multivariable Models
Regression modeling was used to identify pretreatment factors that were associated independently with SVR. Data from 1550 patients with a complete dataset of the covariates of interest were included in the model. We first modeled SVR considering all predictors as dichotomous variables (continuous and ordinal variables were dichotomized according to clinically relevant thresholds 6 ). Multivariable logistic regression using backward selection identified IL-28B type, ethnic background, baseline viral load, hepatic fibrosis stage, and fasting glucose level as being associated independently with SVR (Table 5) . IL-28B type had the greatest odds ratio favoring SVR in this model (CC vs non-CC: odds ratio, 5.2; 95% CI, 4.1-6.7; P Ͻ .0001). A second multivariate logistic regression model was built in which continuous and ordinal variables were not dichotomized, allowing us to use pseudo R-squared values to estimate the contribution of each variable to the variability observed in SVR. IL-28B type (CC vs non-CC) was estimated to explain 14.8% of the variability in treatment response in the cohort, after adjustment for the other independent predictors (Supplementary Table 5 ). Other independent predictors of SVR in this more powerful model included ethnic background, baseline viral load, hepatic fibrosis stage, fasting glucose level, BMI, and RBV starting dose (mg/kg). No other predictor explained more than 5% of the variability in SVR, and the IL-28B type therefore was the strongest pretreatment predictor of SVR. A second important question relates to the informativeness of IL-28B status after viral response at week 4 is known. For those subjects attaining RVR, IL-28B type was not associated with SVR (CC vs non-CC genotype, P ϭ .6734). However, for those who did not attain RVR, IL-28B type had a strong predictive value (P Ͻ .0001). A direct comparison between these 2 groups showed that the predictive value of the IL-28B polymorphism was significantly different (P value for interaction ϭ .0023). A model then was built to consider the independent effects of the IL-28B polymorphism and RVR in the context of the other baseline predictors. RVR had the largest odds ratio for SVR (odds ratio, 9.1; 96% CI, 5.8 -14.0 vs non-RVR non-CC genotype reference) ( Table 5 ). In non-RVR patients, CC genotype was associated independently with SVR (odds ratio, 5.2; 95% CI, 3.9 -6.9 vs non-CC genotypes). An additional term to divide patients who attained RVR by IL-28B polymorphism was not significant.
Analysis of Adherent Patients
We also analyzed the 1137 adherent patients used for the genetic association study 9 (Supplementary Tables  6 -10 , Supplementary Figures 1 and 2 ). The effect of the IL-28B type on treatment response was similar in this subset. SVR rates were higher, consistent with the role for adherence in treatment outcome. 16 
NOTE. Data for SVR include the entire ITT population. Data for on-treatment virologic milestones/relapse rates refer to the number of patients who had the evaluation performed. The trial protocol included a stopping rule for patients who did not attain EVR at week 12 (no EVR ϭ reduction of serum HCV RNA Ͻ2 log 10 IU at week 12). EOTR, end-of-treatment response at week 48; URVR, ultrarapid virologic response at week 2.
Discussion
We previously identified a polymorphism upstream of the IL-28B gene to be associated strongly with SVR in treatment-adherent HCV-1 patients. 9 In this ITT analysis, we present a number of novel insights. The clinical relevance of the genetic discovery was confirmed, irrespective of the degree of treatment adherence. The polymorphism was associated with improved SVR rates by enhancing early viral kinetics, increasing the rates of week 4, week 12, and week 48 viral clearance, and decreasing the rate of posttreatment relapse. Two major benefits of the polymorphism were observed: (1) a higher rate of RVR, which was followed in most cases by an SVR; and (2) a 2-fold increase in the rate of SVR in the majority of patients (Ͼ80%) who did not achieve an RVR. The effect of this polymorphism on treatment response was maintained in Caucasians, African Americans, and Hispanics, in whom the differing allele frequencies contributed very strongly to the racial disparity in overall response rates. Indeed, African American patients with the CC IL-28B type responded better than Caucasian patients with the non-CC IL-28B types. Finally, the strength of this genetic factor as a predictor of treatment response was borne out in the multivariable analysis, where it was the strongest pretreatment predictor of SVR. The key marker for improved treatment response was the CC IL-28B type. The rate of SVR was doubled in patients with the CC compared with the non-CC IL-28B type in all populations. The CC IL-28B type was associated with improved early viral suppression, such that by week 2 of treatment the median reduction in viral load was 2-log 10 IU/mL greater in Caucasian patients with CC versus non-CC genotypes. The more rapid reduction in viral load correlated with increased rates of RVR and cEVR. Relapse rates also were lower in Caucasian and African American patients with the CC IL-28B type.
All patients who attained RVR had a high rate of SVR, although it is important to note that patients with the CC genotype were most likely to reach RVR. In contrast, the IL-28B polymorphism was very important in the non-RVR patients, for whom having a CC genotype increased SVR rates 2-fold. Although viral load sampling was not performed between weeks 4 and 12 of treatment, the viral kinetics predicted that the majority of these CC patients who did not attain an RVR were likely to have become HCV-RNA negative soon after 4 weeks. The weak utility of IL-28B genotype for predicting SVR once the week 12 virologic response was determined, was also consistent with the fact that the major effect of the IL-28B polymorphism was to influence viral kinetics before week 12. Together, these observations emphasize that the major effect of this polymorphism was to increase the rate of early viral decline, leading to higher SVR rates.
The observation that the CC genotype is less frequent in African American patients advances our understanding of the poor response rates seen in this population. 7, 8 However, even in African American patients with the CC genotype, viral kinetics were slower, and rates of RVR, cEVR, and SVR were lower. African American ancestry remained an independent negative predictor of outcome in the multivariable logistic regression. This could suggest the presence of other as yet undetected gene variants that influence treatment response in African Americans compared with Caucasians.
We believe that knowledge of IL-28B type will aid both clinicians and patients in making decisions about pegIFN and RBV therapy. Patients who have the good response CC IL-28B type have a high likelihood of attaining SVR and, in the absence of other concerns regarding suitability for therapy, should be considered ideal candidates. In contrast, patients with the non-CC IL-28B type, especially in the setting of other markers of poor response, such as African American ethnicity, advanced fibrosis, or high viral load, are unlikely to attain SVR. In this setting, the urgency for therapy should be weighed against the expected availability of direct antivirals in the near future. 17 The clinical utility of IL-28B genotyping was compared with that of week 4 viral clearance. Although RVR had a higher positive predictive value for SVR, it cannot be evaluated before therapy and is uncommon in HCV-1 patients. In comparison, the CC genotype, present in 37% of Caucasians, was strongly predictive of SVR, even if RVR was not achieved. It is likely that RVR and IL-28B genotyping will have complementary roles in clinical practice, with IL-28B type having important utility at baseline, and at week 4 for non-RVR patients.
The mechanisms through which IL-28B SNP genotype influences antiviral response to pegIFN and RBV remain unclear. The protein product of IL-28B is IFN--3, 1 of the 3 members of the recently described type 3 IFN family (IFN--1/2/3 ϭ IL-29, IL-28A, and IL-28B). 18, 19 In experimental models, IFN-inhibits both HCV and HBV replication. 20 In co-stimulation experiments, IFN-and IFN-alfa have an additive antiviral effect. 21 Antiviral activity of recombinant IFN--1 (IL-29) has been confirmed in HCV-1 patients. 22 The discovery is therefore biologically plausible, and suggests the IFN-signaling axis as an important new direction for studying natural viral defenses. The data raise a number of important issues. Future studies should address whether IL-28B SNP genotyping may be used to personalize duration of therapy. Whether the IL-28B polymorphism has a role in predicting treatment outcome with the addition of direct antivirals in future HCV treatment regimens needs to be established. The delayed viral kinetics seen in patients with the non-CC genotypes, apparent as early as treatment week 2, might suggest a particular role for the direct antivirals in these patients. The relevance of the IL-28B polymorphism to non-HCV-1 infection is not known. Finally, because the polymorphism is the strongest baseline factor predictive of response, and profoundly effects viral kinetics as early as week 2, current clinical trials investigating direct antivirals on a pegIFN/RBV backbone should be analyzed by IL-28B type, and stratification of patients will need to be considered in the future to balance treatment arms according to IL-28B type.
In conclusion, IL-28B type is the strongest baseline predictor of SVR to pegIFN plus RBV in treatment-naive patients with HCV-1. The good response CC IL-28B type is associated with improved viral kinetics and increased rates of RVR, cEVR, and end-of-treatment response, as well as reduced relapse. Even in patients who do not attain RVR, the CC IL-28B type is associated with high rates of SVR. The data strongly support a future role for IL-28B SNP genotyping as part of a clinical assessment before standard antiviral therapy in individuals chronically infected with HCV-1. (Figure 1 and Supplementary Table 1 ), a value of 10 IU/mL (1 log 10 IU/mL) was substituted for HCV-RNA counts that were below the limit of detection (27 IU/mL). This practice of imputing 1 log 10 IU/mL for all left-censored values will introduce bias to comparisons between genotypes and races, potentially underestimating effect. To reduce the bias, a linear mixed-effects model for longitudinal left-censored data was fit to the log HCV-RNA data with race and genotype as covariates. 1 The results suggest that HCV-RNA level declined 0.5872 log 10 IU/mL/wk more for patients with the CC vs non-CC IL-28B type (95% CI, 0.5416 -0.6328). Even after accounting for IL-28B type, race was still a significant factor in the rate of viral decline. 
